Lundbeck Presents Positive Results For Depressive Disorder Phase II Study
Study compared efficacy of three doses of Lu AA24530, 5mg, 10mg and 20 mg, to that of placebo
Lundbeck announces positive headline results from a dose finding clinical trial with the compound Lu AA24530. It is intended for the treatment of major depressive disorder (MDD).
The primary objective of the study was to compare the efficacy of three doses of Lu AA24530, 5mg, 10mg and 20mg to that of placebo (in terms of change from baseline on the Montgomery-Asberg Depression Rating Scale total score) after six weeks of treatment in patients with MDD. Duloxetine was included as an active reference compound in the trial.
Lu AA24530 consistently produced statistically significant improvements on the primary efficacy endpoint and on key secondary endpoints. The reference compound, duloxetine, also produced significant improvement compared to placebo, thereby validating the study. This trial also demonstrated that Lu AA24530 was well-tolerated, said the company.
Anders Gersel Pedersen, Executive Vice President and HOD for Drug Development at Lundbeck, said: “These findings demonstrate the potential value of Lu AA24530 in the treatment of major depressive disorders. We are pleased with the combination of efficacy and good tolerability for Lu AA24530 which clearly supports the development of the compound as a future treatment option for physicians and patients.”
Related Insight
Suppliers Directory
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.